Market revenue in 2021 | USD 1.9 million |
Market revenue in 2030 | USD 11.8 million |
Growth rate | 22.8% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 31.58% in 2021. Horizon Databook has segmented the UAE non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
The UAE non-alcoholic steatohepatitis biomarkers market growth can be attributed to high financial resources and adequate government funding. Being a high-income country, UAE aims at providing universal access to updated & advanced healthcare services by 2021.
Various initiatives undertaken by the UAE government to create awareness among people are further anticipated to propel market growth. Furthermore, the country is undertaking collaborative efforts for the establishment of a virtual research institute for driving research prospects to identify NASH biomarkers.
Such initiatives are anticipated to create opportunities for market growth in the country. Growing government investments in the healthcare sector are likely to fuel the market growth over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the UAE non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into UAE non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account